Thermo Fisher Scentific
TMO----
Q2 FY2026 EarningsQ2 2026 revenue reached $11.99B, up 10% YoY with 5% organic growth. Laboratory Products and Biopharma Services led with $6.69B (55.8% of total), up 12% YoY. GAAP operating margin expanded 50bps to 17.4%, while adjusted operating margin rose 90bps to 22.8%. Diluted GAAP EPS grew 9% to $4.68, and adjusted EPS increased 13% to $6.03, supported by $1.0B in share repurchases during the quarter.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Thermo Fisher Scentific(TMO) predict that the Revenue is 11.99 B (+10.49%), Beat estimate;the EBIT is 2.735 B (+15.16%), Beat estimate;the EPS is 4.68 (+9.35%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
11.99B10.49%
11.70B7.80%
+0.29B2.69%
EBITExceed expectations
2.73B15.16%
2.60B9.44%
+0.14B5.72%
EPSExceed expectations
4.689.35%
4.443.74%
+0.24005.61%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf